ABX-1431 is primarily used in research settings as a potent and selective inhibitor of monoacylglycerol lipase (MAGL), an enzyme responsible for breaking down endocannabinoids like 2-arachidonoylglycerol (2-AG) in the brain. By inhibiting MAGL, ABX-1431 increases levels of 2-AG, enhancing endocannabinoid signaling. This mechanism has made it a valuable tool compound for studying neurological and psychiatric disorders, including anxiety, chronic pain, and neurodegenerative diseases such as Parkinson’s and Alzheimer’s. It has also shown potential in preclinical models for reducing neuroinflammation and protecting neurons, suggesting possible therapeutic pathways for conditions involving inflammation and excitotoxicity. Due to its ability to modulate the endocannabinoid system without direct activation of cannabinoid receptors, ABX-1431 offers a more targeted approach with potentially fewer side effects than direct agonists. However, it remains strictly a research chemical and is not approved for clinical or therapeutic use in humans.